Author: Author

March 29, 2021 Off

FDA approves new indication for Astellas Pharma’s bladder dysfunction drug

By Author

The U.S. Food and Drug Administration approved a new indication for  Astellas Pharma’s  Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.